Paricalcitol, a vitamin D receptor activator, inhibits tumor formation in a murine model of uterine fibroids

Reproductive Sciences

Volumn 21, Issue 9, 2014, Pages 1108-1119

  Halder, Sunil K ^a   Sharan, Chakradhari ^b   Al Hendy, Omar ^a   Al Hendy, Ayman ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

1,25 dihydroxyvitamin D3; leiomyoma; paricalcitol; uterine fibroids; vitamin D3; Zemplar

Indexed keywords

CALCITRIOL; COLLAGEN; PARICALCITOL; STEROID RECEPTOR; ANTINEOPLASTIC AGENT; CALCITRIOL RECEPTOR; DIHYDROXY-VITAMIN D3; ERGOCALCIFEROL; VITAMIN D;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; DRUG EFFICACY; ESTRUS CYCLE; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; STEROID RELEASE; TUMOR VOLUME; UTERUS MYOMA; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; LEIOMYOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; TRANSFORMED CELL LINE; TUMOR CELL LINE; UTERINE NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOCALCIFEROLS; FEMALE; HUMANS; LEIOMYOMA; MICE; MICE, NUDE; RANDOM ALLOCATION; RATS; RECEPTORS, CALCITRIOL; UTERINE NEOPLASMS; VITAMIN D;

EID: 84907218622     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719114537721     Document Type: Article

References (64)

1. Maruo T, Matsuo H, Samoto T, et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids. 2000;65(10-11):585-592.
2. Walker CL, Burroughs KD, Davis B, Sowell K, Everitt JI, Fuchs-Young R. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J Soc Gynecol Investig. 2000;7(4):249-256.
3. Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293-298.
4. Farhi J, Ashkenazi J, Feldberg D, Dicker D, Orvieto R, Ben Rafael Z. Effect of uterine leiomyomata on the results of in-vitro fertilization treatment. Hum Reprod. 1995;10(10):2576-2578.
5. Eldar-Geva T, Meagher S, Healy DL, MacLachlan V, Breheny S, Wood C. Effect of intramural, subserosal, and submucosal uterine fibroids on the outcome of assisted reproductive technology treatment. Fertil Steril. 1998;70(4):687-691.
6. Surrey ES, Lietz AK, Schoolcraft WB. Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitro fertilization-embryo transfer cycle outcome. Fertil Steril. 2001;75(2):405-410.
7. Hart R, Khalaf Y, Yeong CT, Seed P, Taylor A, Braude P. A prospective controlled study of the effect of intramural uterine fibroids on the outcome of assisted conception. Hum Reprod. 2001;16(11):2411-2417.
8. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United States, 1988-1990. Obstet Gynecol. 1994;83(4):549-555.
9. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol. 1995;172(1 pt 1):14-18.
10. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41(1):105-112.
11. Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012;206(3):211. e211-e219.
12. Shen SH, Fennessy F, McDannold N, Jolesz F, Tempany C. Image-guided thermal therapy of uterine fibroids. Semin Ultrasound CT MR. 2009;30(2):91-104.
13. Al-Hendy A, Salama S. Gene therapy and uterine leiomyoma: a review. Hum Reprod Update. 2006;12(4):385-400.
14. Ezzati M, Norian JM, Segars JH. Management of uterine fibroids in the patient pursuing assisted reproductive technologies. Womens Health (Lond Engl). 2009;5(4):413-421.
15. Hassan MH, Othman EE, Hornung D, Al-Hendy A. Gene therapy of benign gynecological diseases. Adv Drug Deliv Rev. 2009;61(10):822-835.
16. Zhang D, Al-Hendy M, Richard-Davis G, et al. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol. 2010;202(3):289. e281-289.
17. Hassan MH, Salama SA, Zhang D, et al. Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model. Fertil Steril. 2010;93(1):239-250.
18. Norman AW, Bouillon R. Vitamin D nutritional policy needs a vision for the future. Exp Biol Med (Maywood). 2010;235(9):1034-1045.
19. Sabry M, Halder SK, Allah AS, Roshdy E, Rajaratnam V, Al-Hendy A. Serumvitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study. Int J Womens Health. 2013;5:93-100.
20. Baird DD, HillMC, Schectman JM, Hollis BW. Vitamin d and the risk of uterine fibroids. Epidemiology. 2013;24(3):447-453.
21. Paffoni A, Somigliana E, Vigano P, et al. Vitamin D status in women with uterine leiomyomas. J Clin Endocrinol Metab. 2013;98(8):E1374-E1378.
22. Halder SK, Sharan C, Al-Hendy A. 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod. 2012;86(4):116, 1-10.
23. Liu LC, Voors AA, van Veldhuisen DJ, et al. Vitamin D status and outcomes in heart failure patients. Eur J Heart Fail. 2011;13(6):619-625.
24. Freedman LP. Multimeric Coactivator Complexes for Steroid/Nuclear Receptors. Trends Endocrinol Metab. 1999;10(10):403-407.
25. Guyton KZ, Kensler TW, Posner GH. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol. 2001;41:421-442.
26. Meems LM, van der Harst P, van Gilst WH, de Boer RA. Vitamin D biology in heart failure: molecular mechanisms and systematic review. Curr Drug Targets. 2011;12(1):29-41.
27. Nesby-O'Dell S, Scanlon KS, CogswellME, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National health and nutrition examination survey, 1988-1994. Am J Clin Nutr. 2002;76(1):187-192.
28. Holick MF. Too little vitamin D in premenopausal women: why should we care? Am J Clin Nutr. 2002;76(1):3-4.
29. Downes E, Sikirica V, Gilabert-Estelles J, et al. The burden of uterine fibroids in five European countries. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):96-102.
30. Al-Hendy A, Salama SA. Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril. 2006;86(3):686-693.
31. Brandon DD, Bethea CL, Strawn EY, et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol. 1993;169(1):78-85.
32. Brandon DD, Erickson TE, Keenan EJ, et al. Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab. 1995;80(6):1876-1881.
33. Chen TC, Holick MF. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab. 2003;14(9):423-430.
34. Koli K, Keski-Oja J. 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 2000;11(4):221-229.
35. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al. The nuclear receptor superfamily: the second decade. Cell. 1995, 83(6):835-839.
36. Bouillon R, Verstuyf A, Verlinden L, et al. Non-hypercalcemic pharmacological aspects of vitamin D analogs. Biochem Pharmacol. 1995;50(5):577-583.
37. Sharan C, Halder SK, Thota C, Jaleel T, Nair S, Al-Hendy A. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril. 2011;95(1):247-253.
38. Miller GJ. Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev. 1998;17(4):353-360.
39. Meems LM, Cannon MV, Mahmud H, et al. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol. 2012;132(3-5):282-289.
40. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol. 1995;146(6):1568-1579.
41. Al-Hendy A, Auersperg N. Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer: an effective in vitro drug-sensitization system. Gynecol Obstet Invest. 1997;43(4):268-275.
42. Halder SK, Osteen KG, Al-Hendy A. 1,25-dihydroxyvitamin d3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells. Biol Reprod. 2013;89(6):150, 1-13.
43. Mathiasen IS, Lademann U, Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res. 1999;59(19):4848-4856.
44. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308(5728):1589-1592.
45. Stewart EA, Friedman AJ, Peck K, Nowak RA. Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab. 1994;79(3):900-906.
46. Ding L, Xu J, Luo X, Chegini N. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab. 2004;89(11):5549-5557.
47. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006;25(1):99-113.
48. Limper AH, Roman J. Fibronectin. A versatile matrix protein with roles in thoracic development, repair and infection. Chest. 1992, 101(6):1663-1673.
49. Gelse K, Poschl E, Aigner T. Collagens-structure, function, and biosynthesis. Adv Drug Deliv Rev. 2003;55(12):1531-1546.
50. Byers PH. Collagens: building blocks at the end of the development line. Clin Genet. 2000;58(4):270-279.
51. Polgar A, Falus A, Koo E, et al. Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases. Rheumatology (Oxford). 2003;42(4):522-527.
52. Ohara N. A putative role of versican in uterine leiomyomas. Clin Exp Obstet Gynecol. 2009;36(2):74-75.
53. Norian JM, Malik M, Parker CY, Joseph D, Leppert PC, Segars JH, Catherino WH. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci. 2009;16(12):1153-1164.
54. Mujumdar VS, Tyagi SC. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. J Hypertens. 1999;17(2):261-270.
55. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516.
56. Bogusiewicz M, Stryjecka-Zimmer M, Postawski K, Jakimiuk AJ, Rechberger T. Activity of matrix metalloproteinase-2 and -9 and contents of their tissue inhibitors in uterine leiomyoma and corresponding myometrium. Gynecol Endocrinol. 2007;23(9):541-546.
57. Rahman A, Hershey S, Ahmed S, Nibbelink K, Simpson RU. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol. 2007;103(3-5):416-419.
58. Halder SK, Osteen KG, Al-Hendy A. Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum Reprod. 2013;28(9):2407-2416.
59. Nagase H: Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res. 1998;8(3):179-186.
60. Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. JClinInvest. 1996;97(7):1577-1588.
61. Zanello SB, Collins ED, Marinissen MJ, Norman AW, Boland RL. Vitamin D receptor expression in chicken muscle tissue and cultured myoblasts. Horm Metab Res. 1997;29(5):231-236.
62. Mauskopf J, Flynn M, Thieda P, Spalding J, Duchane J. The economic impact of uterine fibroids in the United States: a summary of published estimates. J Womens Health (Larchmt). 2005;14(8):692-703.
63. Halder SK, Goodwin JS, Al-Hendy A. 1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab. 2011;96(4):E754-E762.
64. Flanagan JN, Zheng S, Chiang KC, et al. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res. 2009;29(9):3547-3553.